EP Patent

EP2012769A1 — Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms

Assigned to Rundfeldt Chris · Expires 2009-01-14 · 17y expired

What this patent protects

The present invention is directed to the prevention, reversal and medical treatment of dystonia and dyskinesia as well as other diseases related to movement disorders, both in human beings and animals by administering a neuronal potassium channel opener such as flupirtine, retiga…

USPTO Abstract

The present invention is directed to the prevention, reversal and medical treatment of dystonia and dyskinesia as well as other diseases related to movement disorders, both in human beings and animals by administering a neuronal potassium channel opener such as flupirtine, retigabine or maxipost.

Drugs covered by this patent

Patent Metadata

Patent number
EP2012769A1
Jurisdiction
EP
Classification
—
Expires
2009-01-14
Drug substance claim
No
Drug product claim
No
Assignee
Rundfeldt Chris
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.